Drug Information

Drug General Information
Drug ID
D08OVG
Former ID
DIB016122
Drug Name
CKD-516
Synonyms
S-516; Tubulin polymerization inhibitor (iv, solid cancer), Chong Kun Dang
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [523842]
Company
Chong Kun Dang Pharmaceutical Corp
Formula
C26H29ClN6O5S
Canonical SMILES
c1(nc(cs1)c1cc(c(C(=O)c2cc(c(c(c2)OC)OC)OC)cc1)n1ncnc1)<br />NC(=O)[C@@H](N)C(C)C.Cl
PubChem Compound ID
46929961
Target and Pathway
Target(s) Tubulin beta Target Info Inhibitor [532537]
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Huntington disease
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
Ref 523842ClinicalTrials.gov (NCT01560325) Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers. U.S. National Institutes of Health.
Ref 532537CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.